Oculis Holding (OCS)

Its lead programs include OCS-01, a topical formulation being developed for retinal diseases such as diabetic macular edema. The candidate is designed to bring drug exposure to the posterior segment of the eye through an eye-drop approach, which, if successful, could offer an alternative to more invasive routes commonly used in retinal care. Oculis also advances OCS-02, also known as licaminlimab, a topical biologic candidate for dry eye disease, a large and competitive market where inflammation is a key treatment target.

Another important asset is OCS-05, a neuroprotective candidate being studied for acute optic neuritis and other neuro-ophthalmic disorders. This program gives Oculis exposure to conditions linked to nerve damage and vision loss, including areas such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.

Oculis operates internationally, with a presence across Switzerland, Iceland, France, the United States, and Hong Kong. As a listed biotechnology company, its value is closely tied to clinical trial progress, regulatory milestones, financing capacity, and the competitive landscape in ophthalmic drug development.